As
filed with the Securities and Exchange Commission on October 3, 2024
Registration
No. 333-282358
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-1
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
CINGULATE
INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
2834 |
|
86-3825535 |
(State
or other jurisdiction of
incorporation
or organization) |
|
(Primary
Standard Industrial
Classification
Code Number) |
|
(I.R.S.
Employer
Identification
Number) |
1901
W. 47th Place
Kansas
City, KS 66205
(913)
942-2300
(Address,
including zip code, and telephone number, including
area
code, of registrant’s principal executive offices)
Shane
J. Schaffer
Chief
Executive Officer
Cingulate
Inc.
1901
W. 47th Place
Kansas
City, KS 66205
(913)
942-2300
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Copies
to:
Michael
J. Lerner, Esq.
Steven
M. Skolnick, Esq.
Lowenstein
Sandler LLP
1251
Avenue of the Americas
New
York, New York 10020
(212)
262-6700
Approximate
date of commencement of proposed sale to the public:
From
time to time after this registration statement becomes effective, as determined by the selling stockholder.
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. ☒
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large
accelerated filer ☐ |
|
Accelerated
filer ☐ |
| Non-accelerated
filer ☒ |
|
Smaller
reporting company ☒ |
| |
|
Emerging
growth company ☒ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐
The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY
NOTE
This
Amendment No. 1 (the “Amendment”) is being filed solely to correct a typographical error in the auditor consent filed as
Exhibit 23.1 to the Registration Statement on Form S-1 (File No. 333-282358) (the “Registration Statement”) filed by the
Registrant with the Securities and Exchange Commission on September 26, 2024. Accordingly, this Amendment consists of only the facing page, this explanatory note,
Part II of the Registration Statement, including the signature page, the exhibit index, and a corrected Exhibit 23.1 filed herewith. The
prospectus is unchanged and has therefore been omitted from this filing.
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
13. Other Expenses of Issuance and Distribution.
The
following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other
than underwriting
discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration
fee.
| | |
Amount | |
| Securities and Exchange Commission registration fee | |
$ | 1,125 | |
| Accountants’ fees and expenses | |
| 25,000 | |
| Legal fees and expenses | |
| 100,000 | |
| Miscellaneous | |
| 3,875 | |
| Total expenses | |
$ | 130,000 | |
Item
14. Indemnification of Directors and Officers.
As
permitted by Section 102 of the Delaware General Corporation Law, we have adopted provisions in our amended and restated certificate
of incorporation and bylaws that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care
as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business
judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us
or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:
| ● |
any breach
of the director’s duty of loyalty to us or our stockholders; |
| |
|
| ● |
any act or omission not
in good faith or that involves intentional misconduct or a knowing violation of law; |
| |
|
| ● |
any act related to unlawful
stock repurchases, redemptions or other distributions or payment of dividends; or |
| |
|
| ● |
any transaction from which
the director derived an improper personal benefit. |
These
limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our amended and
restated certificate of incorporation also authorizes us to indemnify our officers, directors and other agents to the fullest extent
permitted under Delaware law.
As
permitted by Section 145 of the Delaware General Corporation Law, our bylaws provide that:
| ● |
we may indemnify
our directors, officers, and employees to the fullest extent permitted by the Delaware General Corporation Law, subject to limited
exceptions; |
| |
|
| ● |
we may advance expenses
to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the Delaware General
Corporation Law, subject to limited exceptions; and |
| |
|
| ● |
the rights provided in our bylaws are not exclusive. |
Our
amended and restated certificate of incorporation, filed as Exhibit 3.1 hereto, and our amended and restated bylaws, filed as Exhibit
3.2 hereto, provide for the indemnification provisions described above and elsewhere herein. We have entered into and intend to continue
to enter into separate indemnification agreements with our directors and elective officers which may be broader than the specific indemnification
provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require us, among other things,
to indemnify our officers and directors against liabilities that may arise by reason of their status or service as directors or officers,
other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses
incurred by the directors or officers as a result of any proceeding against them as to which they could be indemnified. In addition,
we have purchased a policy of directors’ and officers’ liability insurance that insures our directors and officers against
the cost of defense, settlement or payment of a judgment in some circumstances. These indemnification provisions and the indemnification
agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement
of expenses incurred, arising under the Securities Act.
Item
15. Recent Sales of Unregistered Securities.
On
July 19, 2021, the Company issued one share of its common stock, par value $0.0001 per share, to Cingulate Therapeutics, LLC for $0.024.
Such issuance was exempt from registration under 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.
On
September 29, 2021, the Company issued 29,762 shares of its common stock, par value $0.0001 per share, to the former holders of units
of Cingulate Therapeutics LLC in connection with the Reorganization Merger. Such issuances were exempt from registration under 4(a)(2)
of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.
On
August 9, 2022, Cingulate Therapeutics LLC issued a $5 million promissory note (the “August Note”) to Werth Family Investment
Associates LLC (“WFIA”). Peter J. Werth, a member of the Company’s Board of Directors is the manager of WFIA. Such
issuance was exempt from registration under 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.
On May 9, 2023, Cingulate Therapeutics LLC amended and restated the August Note to increase the principal amount to $8.0 million (as
so amended and restated, the “Amended and Restated Note”). WFIA had the right during the first five business days of each
calendar quarter to demand payment of all outstanding principal and interest 120 days following notice to Cingulate Therapeutics LLC.
Cingulate Therapeutics LLC was permitted to repay the WFIA Note, in whole or in part, without premium or penalty; provided, that no amount
repaid was permitted to be reborrowed. Such issuance was exempt from registration under 4(a)(2) of the Securities Act of 1933, as amended,
and Regulation D promulgated thereunder.
On
April 24, 2023, the Company completed a private placement to Lincoln Park Capital Fund, LLC (“Lincoln Park”) pursuant to
which it has the right to sell to Lincoln Park up to $12.0 million in shares of common stock, subject to certain limitations, from time
to time over the 36-month period commencing on the date that a registration statement covering the resale of the shares is declared effective
by the SEC (the “LP Purchase Agreement”). The Company issued 1,535 Commitment Shares to Lincoln Park as consideration for
its commitment to purchase shares under the LP Purchase Agreement. In the LP Purchase Agreement, Lincoln Park represented to the Company,
among other things, that it was an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the
Securities Act). The securities were and will be sold by the Company under the Purchase Agreement in reliance upon an exemption from
the registration requirements under the Securities Act afforded by Section 4(a)(2) of the Securities Act.
On
August 11, 2023, the Company entered into a Securities Purchase Agreement with Werth Family Investment Associates LLC, and issued, in
a private placement priced at the market under Nasdaq rules, 7,597 shares of the Company’s common stock at a purchase price per
share of $131.64, for aggregate gross proceeds to the Company of approximately $1.0 million, before deducting transaction expenses payable
by the Company (the “Private Placement”). The Private Placement closed on August 11, 2023. Such issuance was exempt from
the registration requirements under the Securities Act afforded by Section 4(a)(2) of the Securities Act.
On
September 8, 2023, the Company and CTx entered into a note conversion agreement with WFIA (the “Note Conversion Agreement”),
pursuant to which WFIA agreed to convert the $5,000,000 under the Amended and Restated Note plus all accrued interest thereon, or $5,812,500,
into pre-funded warrants (“WIFA Pre-Funded Warrants”) to purchase 28,493 shares of common stock, at a conversion price per
Pre-Funded Warrant of $204.00. The Pre-Funded Warrants have no expiration date and are exercisable immediately at an exercise price of
$0..024 per share. Such issuance was exempt from the registration requirements under the Securities Act afforded by Section 4(a)(2) of
the Securities Act.
On
January 25, 2024, Cingulate Inc. and CTx entered into a Note Conversion Agreement (the “January 2024 Note Conversion Agreement”)
with WFIA, pursuant to which WFIA agreed to convert the remaining $3.0 million of principal under the WFIA Note plus all accrued interest
thereon, or $3,287,500, into pre-funded warrants (the “January WFIA Pre-Funded Warrants”) to purchase 57,254 shares of our
common stock, at a conversion price per January WFIA Pre-Funded Warrant of 57.42. The closing price of the common stock on Nasdaq on
January 24, 2024 was $52.20 per share. The January WFIA Pre-Funded Warrants have no expiration date and are exercisable immediately at
an exercise price of $0.0012 per share, to the extent that after giving effect to such exercise, WFIA and its affiliates would beneficially
own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of our common stock. On March 25,
2024, the Company issued to WFIA an additional pre-funded warrant to purchase 588 shares of common stock as a result of an error in the
interest calculation, on the same form and at the same conversion price as the January WFIA Pre-Funded Warrants. Such issuances were
exempt from the registration requirements under the Securities Act afforded by Section 4(a)(2) of the Securities Act.
On
December 1, 2023, the Company issued 96 shares of common stock at a value of $73.44 per share to a consultant. Such issuance was exempt
from the registration requirements under the Securities Act afforded by Section 4(a)(2) of the Securities Act.
On
February 1, 2024, the Company issued 596 shares of common stock at a value of $40.32 per share to a consultant. Such issuance was exempt
from the registration requirements under the Securities Act afforded by Section 4(a)(2) of the Securities Act.
On
June 10, 2024, the Company issued 11,652 shares of common stock to a consultant at a value of $8.45 per share. Such issuance was exempt
from registration under Section 4(a)(2) under the Securities Act.
On
June 28, 2024, the Company entered into an inducement offer letter agreement (the “Inducement Letter”) with certain holders
(the “Holders”) of certain existing warrants to purchase up to an aggregate of 265,625 shares of its common stock issued
to the Holders on February 6, 2024 (the “Existing Warrants”). Pursuant to the Inducement Letter, the Holders agreed to exercise
for cash its Existing Warrants at a reduced exercise price of $7.02 per share in consideration for the Company’s agreement to issue
in a private placement (i) new series C common stock purchase warrants to purchase an aggregate of 354,167 shares of common stock and
(ii) new series D common stock purchase warrants to purchase an aggregate of 177,084 shares of common stock. Such issuances were exempt
from the registration requirements under the Securities Act afforded by Section 4(a)(2) of the Securities Act.
Item
16. Exhibits and Financial Statement Schedules
| 4.14 |
|
Form of Placement Agent Warrant |
|
8-K |
|
4.4 |
|
2/7/2024 |
| 4.15 |
|
Form of March 2024 WFIA Pre-Funded Warrant |
|
10-K |
|
4.16 |
|
4/1/2024 |
| 4.16 |
|
Form of New Warrant (July 2024 Offering) |
|
8-K |
|
4.1 |
|
7/1/2024 |
| 4.17 |
|
Form of Placement Agent Warrant (July 2024 Offering) |
|
8-K |
|
4.2 |
|
7/1/2024 |
| 5.1* |
|
Opinion of Lowenstein Sandler LLP |
|
|
|
|
|
|
| 10.1# |
|
Patent and Know-How License Agreement, dated August 8, 2018, between BDD Pharma Limited, Cingulate Therapeutics LLC and Drug Delivery International Limited |
|
S-1 |
|
10.2 |
|
9/9/2021 |
| 10.2# |
|
Master Services Agreement between Cingulate Therapeutics LLC and Societal CDMO, Inc., dated October 24, 2022 |
|
8-K |
|
10.1 |
|
10/25/2022 |
| 10.3+ |
|
Employment Agreement, dated September 23, 2021, between Cingulate Therapeutics LLC and Shane J. Schaffer |
|
S-1 |
|
10.4 |
|
9/27/2021 |
| 10.4+ |
|
Employment Agreement, dated September 23, 2021, between Cingulate Therapeutics LLC and Matthew N. Brams |
|
S-1 |
|
10.5 |
|
9/27/2021 |
| 10.5+ |
|
Employment Agreement, dated September 23, 2021, between Cingulate Therapeutics LLC and Laurie A. Myers |
|
S-1 |
|
10.6 |
|
9/27/2021 |
| 10.6+ |
|
Employment Agreement, dated September 23, 2021, between Cingulate Therapeutics LLC and Craig S. Gilgallon |
|
S-1 |
|
10.7 |
|
9/27/2021 |
| 10.7+ |
|
Employment Agreement, dated September 23, 2021, between Cingulate Therapeutics LLC and Louis G. Van Horn |
|
S-1 |
|
10.8 |
|
9/27/2021 |
| 10.8+ |
|
Employment Agreement, dated September 23, 2021, between Cingulate Therapeutics LLC and Raul R. Silva |
|
S-1 |
|
10.9 |
|
9/27/2021 |
| 10.9+ |
|
Amendment to Employment Agreement, effective April 1, 2022, between Cingulate Therapeutics LLC and Raul R. Silva |
|
10-Q |
|
10.1 |
|
8/11/2022 |
| 10.10+ |
|
Amendment to Employment Agreement, effective January 1, 2023, between Cingulate Therapeutics LLC and Raul R. Silva |
|
10-K |
|
10.10 |
|
3/10/2023 |
| 10.11+ |
|
Form of Indemnification Agreement |
|
S-1 |
|
10.10 |
|
9/9/2021 |
| 10.12+ |
|
Cingulate Inc. 2021 Omnibus Equity Incentive Plan |
|
S-1 |
|
10.1 |
|
9/27/2021 |
| 10.13+ |
|
Form of Nonqualified Stock Option Award under 2021 Plan |
|
10-Q |
|
10.1 |
|
5/12/2022 |
| 10.14+ |
|
Form of Incentive Stock Option Award under 2021 Plan |
|
10-Q |
|
10.2 |
|
5/12/2022 |
| 10.15+ |
|
Form of Restricted Stock Unit Award under 2021 Plan |
|
S-1 |
|
10.20 |
|
9/27/2021 |
| 10.16+ |
|
Form of Restricted Stock Award under 2021 Plan |
|
S-1 |
|
10.21 |
|
9/27/2021 |
| 10.17 |
|
Amended and Restated Promissory Note, dated May 9, 2023, between Cingulate Therapeutics, LLC and Werth Family Investment Associates |
|
8-K |
|
10.1 |
|
5/10/2023 |
| 10.18 |
|
At The Market Offering Agreement, dated January 3, 2023, by and between Cingulate Inc. and H.C. Wainwright & Co., LLC |
|
S-3 |
|
1.2 |
|
1/3/2023 |
| 10.19 |
|
Amendment to ATM Agreement, dated May 2, 2023, by and between Cingulate Inc. and H.C. Wainwright & Co., LLC |
|
10-Q |
|
10.5 |
|
5/10/2023 |
| 10.20 |
|
Joint Commercialization Agreement, dated March 7, 2023, by and between Cingulate Therapeutics, LLC and Indegene, Inc. |
|
10-K |
|
10.19 |
|
3/10/2023 |
| 10.21 |
|
Purchase Agreement, dated April 24, 2023, by and between Lincoln Park Capital, LLC and Cingulate Inc. |
|
8.K |
|
10.1 |
|
4/25/2023 |
| 10.22 |
|
Registration Rights Agreement, dated April 24, 2023, by and between Lincoln Park Capital, LLC and Cingulate Inc. |
|
8.K |
|
10.2 |
|
4/25/2023 |
| 10.23 |
|
Securities Purchase Agreement, dated August 11, 2023, by and between the Company and Werth Family Investment Associates LLC |
|
8-K |
|
10.1 |
|
8/14/2023 |
| 10.24 |
|
Form of Securities Purchase Agreement |
|
S-1 |
|
10.24 |
|
9/7/2023 |
| 10.25 |
|
Note Conversion Agreement, dated September 8, 2023, by and between the Company, Cingulate Therapeutics, LLC and Werth Family Investment Associates LLC |
|
8-K |
|
10.1 |
|
9/11/2023 |
| 10.26+ |
|
Amendment to Employment Agreement, effective January 1, 2024, between Cingulate Therapeutics, LLC and Matthew N. Brams |
|
S-1 |
|
10.26 |
|
1/12/2024 |
| 10.27+ |
|
Amendment to Employment Agreement, effective December 29, 2023, between Cingulate Therapeutics, LLC and Raul A. Silva |
|
S-1 |
|
10.27 |
|
1/12/2024 |
| 10.28 |
|
Note Conversion Agreement, dated January 25, 2024, by and between the Company, Cingulate Therapeutics, LLC and Werth Family Investment Associates LLC |
|
8-K |
|
10.1 |
|
1/29/2024 |
| 10.29+ |
|
Employment Agreement, dated January 25, 2024, between Cingulate Therapeutics LLC, and Jennifer L. Callahan |
|
8-K |
|
10.2 |
|
1/29/2024 |
| 10.30 |
|
Form of Securities Purchase Agreement |
|
8-K |
|
10.1 |
|
2/07/2024 |
| 10.31+ |
|
Amendment No.1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan |
|
8-K |
|
10.1 |
|
6/12/2024 |
| 10.32 |
|
Form of Inducement Letter |
|
8-K |
|
10.1 |
|
7/01/2024 |
| 21.1 |
|
List of Subsidiaries of Cingulate Inc. |
|
10-K |
|
21.1 |
|
4/1/2024 |
| 23.1** |
|
Consent of Independent Registered Public Accounting Firm |
| 23.2* |
|
Consent of Lowenstein Sandler LLP (included in Exhibit 5.1) |
| 24.1* |
|
Power of Attorney (contained in the signature page of this registration statement) |
| 107* |
|
Filing Fee Table |
†
Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby undertakes to
furnish supplementally a copy of any of the omitted schedules and exhibits to the SEC on a confidential basis upon request.
*
Previously filed
**
Filed herewith
+
Indicates a management contract or compensatory plan
#
Certain portions of this exhibit have been omitted because the omitted information is (i) not material and (ii) would likely cause competitive
harm to the Company if publicly disclosed.
Item
17. Undertakings.
The
undersigned registrant hereby undertakes to
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate,
the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation
of Registration Fee” table in the effective registration statement; and
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement;
provided,
however, that paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant
pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration
statement.
(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(4)
For the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b)
as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A (§230.430A of this chapter), shall be deemed to be part of and included in the registration statement
as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus
that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such date of first use.
(5)
That for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser:
(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
424;
(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
the undersigned registrant;
(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and
(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser
(6)
That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report
pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit
plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering
of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(7)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of
the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim
for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer
or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant
to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Kansas City, Kansas, on the day of October 3, 2024.
| |
CINGULATE
INC. |
| |
|
| |
By: |
/s/
Shane J. Schaffer |
| |
Name: |
Shane J. Schaffer |
| |
Title: |
Chief Executive Officer |
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities
held on the dates indicated:
| Signature |
|
Title |
|
Date |
| |
|
|
|
|
| /s/
Shane J. Schaffer |
|
|
|
|
| Shane J. Schaffer |
|
Chief Executive Officer, Chairman (Principal Executive
Officer) |
|
October
3, 2024 |
| |
|
|
|
|
| /s/
Jennifer L. Callahan |
|
|
|
|
| Jennifer L. Callahan |
|
Chief Financial Officer (Principal Financial Officer
and Principal Accounting Officer) |
|
October
3, 2024 |
| |
|
|
|
|
| * |
|
|
|
October
3, 2024 |
| Peter J. Werth |
|
Director |
|
|
| |
|
|
|
|
| * |
|
|
|
October
3, 2024 |
| Bryan Lawrence |
|
Director |
|
|
| |
|
|
|
|
| * |
|
|
|
October
3, 2024 |
| Jeffrey Ervin |
|
Director |
|
|
| |
|
|
|
|
| * |
|
|
|
October
3, 2024 |
| John Roberts |
|
Director |
|
|
| *By: |
/s/
Shane J. Schaffer |
|
| |
Shane
J. Schaffer |
|
| |
Attorney-in-Fact |
|
Exhibit
23.1
Consent
of Independent Registered Public Accounting Firm
We
consent to the use of our report dated April 1, 2024, with respect to the consolidated financial statements of Cingulate Inc.,
incorporated herein by reference, and to the reference to our firm under the heading “Experts” in the prospectus.
/s/
KPMG LLP
St.
Louis, Missouri
September
26, 2024
Cingulate (NASDAQ:CINGW)
過去 株価チャート
から 10 2024 まで 11 2024
Cingulate (NASDAQ:CINGW)
過去 株価チャート
から 11 2023 まで 11 2024
